Arsonoliposomes for the Potential Treatment of Medulloblastoma

• Published in: Pharmaceutical research Vol. 26; no. 10; pp. 2237 - 2246
• Main Authors: Favretto, Marco E, Marouf, Showan, Ioannou, Panagiotis, Antimisiaris, Sophia G, Parker, Terence L, Kallinteri, Paraskevi
• Format: Journal Article
• Language: English
• Published: Boston Boston : Springer US 01.10.2009; Springer US; Springer; Springer Nature B.V
• Subjects: 3T3 Cells; Animals; Antineoplastic Agents - administration & dosage; Antineoplastic Agents - pharmacokinetics; Apoptosis; Arsenicals - administration & dosage; Arsenicals - pharmacokinetics; Biochemistry; Biological and medical sciences; Biomedical and Life Sciences; Biomedical Engineering and Bioengineering; Biomedicine; Brain cancer; Cell Line, Tumor; Cell Survival - drug effects; Cell Survival - physiology; Cellular biology; Dose-Response Relationship, Drug; Drug Delivery Systems - methods; Endocytosis - physiology; General pharmacology; Liposomes; Medical Law; Medical sciences; Medulloblastoma - drug therapy; Medulloblastoma - metabolism; Mice; Original Article; Pharmaceutical technology. Pharmaceutical industry; Pharmacology; Pharmacology. Drug treatments; Pharmacology/Toxicology; Pharmacy; Toxicity; Treatment Outcome; arsonoliposomes; apoptosis; liposomes; medulloblastoma; cellular uptake; Nervous system diseases; Pharmaceutical technology; Liposome; Malignant tumor; In vitro; Uptake; Cerebral disorder; Treatment; Cell death; Medulloblastoma; Central nervous system disease; Cancer; Apoptosis

Purpose To investigate the arsonoliposome effect on medulloblastoma cells (VC312Rs) related to uptake, endocytotic mechanism and cell viability. Methods VC312R viability in presence of either arsonoliposomes or stealth liposomes was studied using MTT assay for 1-4 days. Fibroblasts (3T3) were used a...